The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Diabetes-related foot ulcers (DFUs) and their sequelae result in large patient and societal burdens. Long-term data determining the efficacy of individual glucose-lowering agents on DFUs are lacking. Using existing data from the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, we conducted post hoc analyses assessing the impact of liraglutide versus placebo in people with type 2 diabetes and at high risk of cardiovascular (CV) events on the incidence of DFUs and their sequelae. RESEARCH DESIGN AND METHODS: The LEADER trial (NCT01179048) was a randomized, double-blind, multicenter, CV outcomes trial assessing liraglutide (1.8 mg/day) versus placebo, in addition to standard of care, for up to 5 years. Information on DFUs was collected systematically during the trial, and DFU complications were assessed post hoc through reviewing case narratives. RESULTS: During a median of 3.8 years’ follow-up, similar proportions of patients reported at least one episode of DFU in the liraglutide and placebo groups (3.8% [176/4,668] versus 4.1% [191/4,672], respectively; hazard ratio [HR] 0.92 [95% CI 0.75, 1.13; P = 0.41]). Analysis of DFU-related complications demonstrated a significant reduction in amputations with liraglutide versus placebo (HR 0.65 [95% CI 0.45, 0.95; P = 0.03]). However, no differences were found for foot infections, involvement of underlying structures, or peripheral revascularization in the main analysis. CONCLUSIONS: Treatment with liraglutide in patients with type 2 diabetes and at high risk of CV events in the LEADER trial did not increase the risk of DFU events and was associated with a significantly lower risk of DFU-related amputations compared with placebo. This association, possibly due to chance, needs further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Diamicron MR Controlled Evaluation (ADVANCE) studies, but DFU was not a specified end point in these trials (11,20,21).”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“In the Veterans Affairs Diabetes Trial (VADT), amputation due to ischemic gangrene was included within the composite primary end point, but data related to amputation or foot ulcers only do not appear to have been published (22,23).”
BackgroundDiabetic foot ulcers and their recurrence
Armstrong, D. G., Boulton, A. J. M., & Bus, S. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1615439 · Cited by 4,376
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414266 · Cited by 668 · cited 1×
“In the Veterans Affairs Diabetes Trial (VADT), amputation due to ischemic gangrene was included within the composite primary end point, but data related to amputation or foot ulcers only do not appear to have been published (22,23).”
BackgroundHingorani, A., LaMuraglia, G. M., Henke, P., Meissner, M. H., Loretz, L., Zinszer, K. M., Driver, V. R., Frykberg, R., Carman, T. L., Marston, W., et al. (2016) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.10.003 · Cited by 641
Burden of Diabetic Foot Ulcers for Medicare and Private Insurers
Rice, J. B., Desai, U., Cummings, A. K. G., Birnbaum, H. G., Skornicki, M., & Parsons, N. B. (2014) · Diabetes Care · doi:10.2337/dc13-2176 · Cited by 624
Amputation and Mortality in New-Onset Diabetic Foot Ulcers Stratified by Etiology
Moulik, P. K., Mtonga, R., & Gill, G. V. (2003) · Diabetes Care · doi:10.2337/diacare.26.2.491 · Cited by 613
Mant, J., Doust, J., Roalfe, A., Barton, P., Cowie, M., Glasziou, P., Mant, D., McManus, R., Holder, R., Deeks, J., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13320 · Cited by 498
Neuropathy and Diabetic Foot Syndrome
Volmer-Thole, M., & Lobmann, R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060917 · Cited by 407
Rajamani, K., Colman, P. G., Li, L. P., Best, J. D., Voysey, M., D'Emden, M. C., Laakso, M., Baker, J. R., & Keech, A. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60698-x · Cited by 328
Black, C., Clar, C., Henderson, R., MacEachern, C., McNamee, P., Quayyum, Z., Royle, P., & Thomas, S. (2009) · Health Technology Assessment · doi:10.3310/hta13520 · Cited by 291
Jeffcoate, W. J., Bus, S. A., Game, F. L., Hinchliffe, R. J., Price, P. E., & Schaper, N. C. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30012-2 · Cited by 234
Impact of Chronic Kidney Disease on Survival After Amputation in Individuals With Diabetes
Lavery, L. A., Hunt, N. A., Ndip, A., Lavery, D. C., Van Houtum, W., & Boulton, A. J. M. (2010) · Diabetes Care · doi:10.2337/dc10-1213 · Cited by 217
10. Microvascular Complications and Foot Care
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s013 · Cited by 181
Verma, S., Mazer, C. D., Al-Omran, M., Inzucchi, S. E., Fitchett, D., Hehnke, U., George, J. T., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.117.032031 · Cited by 166
Gaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113481817 · Cited by 148
Self-citationHasan, R., Firwana, B., Elraiyah, T. A., Domecq, J. P., Prutsky, G. J., Nabhan, M., Prokop, L. J., Henke, P. K., Τσάπας, Α., Montori, V. M., et al. (2016) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.10.005 · Cited by 145
Jeffcoate, W., Price, P., Phillips, C., Game, F., Mudge, E., Davies, S., Amery, C., Edmonds, M., Gibby, O., Johnson, A., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13540 · Cited by 119
Long, M., Cai, L., Li, W., Zhang, L., Guo, S., Zhang, R., Zheng, Y., Liu, X., Wang, M., Zhou, X., et al. (2017) · Diabetes · doi:10.2337/db17-0934 · Cited by 105
A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers
Elraiyah, T. A., Τσάπας, Α., Prutsky, G. J., Domecq, J. P., Hasan, R., Firwana, B., Nabhan, M., Prokop, L. J., Hingorani, A., Claus, P. L., et al. (2016) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.10.007 · Cited by 100
Petrakis, I., Kyriopoulos, I. J., Ginis, A., & Athanasakis, K. (2017) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2017.1305891 · Cited by 68
Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing.
Roan, J.-N., Cheng, H.-N., Young, C., Lee, C.-J., Yeh, M.-L., Luo, C.-Y., Tsai, Y., & Lam, C. (2017) · Journal of Surgical Research · doi:10.1016/j.jss.2016.09.024 · Cited by 57
Cited by
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Lower Extremity Peripheral Artery Disease Without Chronic Limb-Threatening Ischemia: A Review
Polonsky, T. S., & McDermott, M. M. (2021) · JAMA · doi:10.1001/jama.2021.2126 · Cited by 198
Lower extremity arterial disease in patients with diabetes: a contemporary narrative review
Nativel, M., Potier, L., Alexandre, L., Baillet-Blanco, L., Ducasse, E., Velho, G., Marre, M., Roussel, R., Rigalleau, V., & Mohammedi, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0781-1 · Cited by 194
Bonaca, M. P., Catarig, A.-M., Houlind, K., Ludvik, B., Nordanstig, J., Ramesh, C. K., Rasouli, N., Sourij, H., Videmark, A., & Verma, S. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00509-4 · Cited by 176
Contemporary Medical Management of Peripheral Artery Disease
Bonaca, M. P., Hamburg, N. M., & Creager, M. A. (2021) · Circulation Research · doi:10.1161/circresaha.121.318258 · Cited by 161
Metadata
- Authors
- Dhatariya, K., Bain, S. C., Buse, J. B., Simpson, R., Tarnow, L., Kaltoft, M. S., Stellfeld, M., Tornøe, K., Pratley, R. E., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators
- Affiliations
- Norfolk and Norwich University Hospital (GB)
- University of East Anglia (GB)
- Corresponding author
- Dhatariya, Ketan
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-08-02
- Volume
- 41
- Issue
- 10
- Pages
- 2229-2235
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6150424
- OpenAlex
- W2883426762
- Semantic Scholar
- 27723cc2089089c747770bb1f4a89c5cf9dd9df2
- Cited by
- 141
- References
- 30
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 19 · 2023: 20 · 2022: 21 · 2021: 16 · 2020: 10 · 2019: 10 · 2018: 2
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- liraglutide, diabetic foot ulcer, type 2 diabetes, amputation, foot infection, peripheral revascularization, cardiovascular risk, GLP-1 receptor agonists, LEADER trial, post hoc analysis
- MeSH terms
- Liraglutide, Aged, Amputation, Surgical, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Diabetic Foot
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.